Pathogenesis of systemic lupus erythematosus

Journal of Clinical Pathology

Volumn 56, Issue 7, 2003, Pages 481-490

  Mok, C C ^a   Lau, C S ^b  

^a TUEN MUN HOSPITAL   (Hong Kong)

^b QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINE; AUTOANTIBODY; AUTOANTIGEN; BACTERIAL DNA; CANAVANINE; CD4 ANTIGEN; CD8 ANTIGEN; CHLORPROMAZINE; CYTOKINE; DNA ANTIBODY; ESTROGEN; HAIR DYE; HLA ANTIGEN; HYDRALAZINE; HYDRAZINE DERIVATIVE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; ISONIAZID; LUPUS ANTICOAGULANT; MAJOR HISTOCOMPATIBILITY ANTIGEN; ORAL CONTRACEPTIVE AGENT; PENICILLAMINE; PHENYTOIN; PROCAINAMIDE; RIBONUCLEOPROTEIN; SATURATED FATTY ACID; SMALL NUCLEAR RIBONUCLEOPROTEIN; TOBACCO SMOKE;

ALFALFA; ANTIGEN PRESENTING CELL; APOPTOSIS; B LYMPHOCYTE; CIGARETTE SMOKING; DIETARY INTAKE; DISEASE ACTIVITY; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; FAT INTAKE; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMUNOREGULATION; LUPUS ERYTHEMATOSUS; MENSTRUAL CYCLE; ORAL CONTRACEPTION; PATHOGENESIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RETROVIRUS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; ULTRAVIOLET IRRADIATION;

ANTIBODY FORMATION; AUTOANTIBODIES; B-LYMPHOCYTES; CYTOKINES; FEMALE; GENES, MHC CLASS II; GENETIC PREDISPOSITION TO DISEASE; HLA-DR2 ANTIGEN; HLA-DR3 ANTIGEN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; POLYMORPHISM, GENETIC; SELF TOLERANCE; TH1 CELLS; TH2 CELLS;

EID: 0037668545     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.7.481     Document Type: Review

References (147)

1. Pisetsky DS. Systemic lupus erythematosus. A. Epidemiology, pathology and pathogenesis. In: Klippel JH, ed. Primer on the rheumatic diseases, 11th ed. Georgia, USA: Arthritis Foundation, 1997:246-51.
2. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998;199:265-85.
3. Schur PH. Genetics of systemic lupus erythematosus. Lupus 1995;4:425-37.
4. Atkinson JP. Complement activation and complement receptors in systemic lupus erythematosus. Springer Semin Immunopathol 1986;9:179-94.
5. Sullivan KE. Genetics of systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 2000;26:229-56.
6. Yun HR, Koh HK, Kim SS, et al. FcgammaRIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients. Lupus 2001;10:466-72.
7. Salmon JE, Millard S, Schachter LA, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
8. Koene HR, Kleijer M, Swaak AJ, et al. The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. Arthritis Rheum 1998;41:1813-18.
9. Zuniga R, Ng S, Peterson MG, et al. Low-binding alleles of Fcgamma receptor types IIA and IIIa are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients. Arthritis Rheum 2001;44:361-7.
10. Ip WK, Chan SY, Lau CS, et al. Association of systemic lupus erythematosus with promoter polymorphisms of the mannose-binding lectin gene. Arthritis Rheum 1998;41:1663-8.
11. Vyse TJ, Kotzin BL. Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol 1998;16:261-92.
12. Tsao BP. An update on genetic studies of systemic lupus erythematosus. Curr Rheumatol Rep 2002;4:359-67.
13. Moser KL, Gray-McGuire C, Kelly J, et al. Confirmation of genetic linkage between human systemic lupus erythematosus and chromosome 1q41. Arthritis Rheum 1999;42:1902-7.
14. Gray-McGuire C, Moser KL, Gaffney PM, et al. Genome scan of human systemic lupus erythematosus by regression modeling: evidence of linkage and epistasis at 4p16-15.2. Am J Hum Genet 2000;67:1460-9.
15. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993;72:113-24.
16. Formiga F, Moga I, Pac M, et al. Mild presentation of systemic lupus erythematosus in elderly patients assessed by SLEDAI. Lupus 1999;8:462-5.
17. French MA, Hughes P. Systemic lupus erythematosus and Klinefelter's syndrome. Ann Rheum Dis 1983;42:471-3.
18. Lahita RG, Bradlow HL, Kunkel HG, et al. Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum 1979;22:1195-8.
19. Jungers P, Nahoul K, Pelissier C, et al. Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum 1982;25:454-7.
20. Lahita RG, Bradlow HL, Ginzler E, et al. Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum 1987;30:241-8.
21. Lahita RG, Kunkel HG, Bradlow HL. Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum 1983;26:1517-21.
22. Folomeev M, Dougados M, Beaune J, et al. Plasma sex hormones and aromatase activity in tissues of patients with systemic lupus erythematosus. Lupus 1992;1:191-5.
23. Sequeira JF, Keser G, Greenstein B, et al. Systemic lupus erythematosus: sex hormones in male patients. Lupus 1993;2:315-17.
24. Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus 2000;9:252-7.
25. Sthoeger ZM, Chiorazzi N, Lahita RG. Regulation of the immune response by sex hormones. I. In vitro effects of estradiol and testosterone on pokeweed mitogen-induced human B cell differentiation. J Immunol 1988;141:91-8.
26. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human peripheral blood mononuclear cells. J Allergy Clin Immunol 1999;103:282-8.
27. Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1999;42:328-37.
28. Evans MJ, MacLaughlin S, Marvin RD, et al. Estrogen decreases in vitro apoptosis of peripheral blood mononuclear cells from women with normal menstrual cycles and decreases TNF-alpha production in SLE but not in normal cultures. Clin Immunol Immunopathol 1997;82:258-62.
29. Wyle FA, Kent JR. Immunosuppression by sex steroid hormones. The effect upon PHA- and PPD-stimulated lymphocytes. Clin Exp Immunol 1977;27:407-15.
30. McMurray RW, Ndebele K, Hardy KJ, et al. 17-beta-estradiol suppresses IL-2 and IL-2 receptor. Cytokine 2001;14:324-33.
31. Rider V, Foster RT, Evans M, et al. Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus. Clin Immunol Immunopathol 1998;89:171-80.
32. Rider V, Jones S, Evans M, et al. Estrogen increases CD40 ligand expression in T cells from women with systemic lupus erythematosus. J Rheumatol 2001;28:2644-9.
33. Kanda N, Tsuchida T, Tamaki K. Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exp Immunol 1996;106:410-15.
34. Kanda N, Tsuchida T, Tamaki K. Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:1703-11.
35. Suzuki T, Suzuki N, Daynes RA, et al. Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells. Clin Immunol Immunopathol 1991;61:202-10.
36. Suzuki T, Suzuki N, Engleman EG, et al. Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 1995;99:251-5.
37. Sanchez-Guerrero J, Liang MH, Karlson EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995;122:430-3.
38. Sanchez-Guerrero J, Karlson EW, Liang MH, 122. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1997;40:804-8.
39. Meier CR, Sturkenboom MC, Cohen AS, et al. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol 1998;25:1515-19.
40. Rose E, Pillsbury DM. Lupus erythematosus (erythematodes) and ovarian function: observations on a possible relationship, with report of six cases. Ann Intern Med 1944;21:1022-34.
41. Mok CC, Wong RWS. Pregnancy in systemic lupus erythematosus. Postgrad Med J 2001;77:157-65.
42. Mok CC, Lau CS, Wong RWS. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum 2001;30:426-35.
43. Le Thi Huong D, Wechsler B, Piette JC, et al. Risks of ovulation-induction therapy in systemic lupus erythematosus. Br J Rheumatol 1996;35:1184-6.
44. Guballa N, Sammaritano L, Schwartzman S, et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 2000;43:550-6.
45. Mok CC, Lau CS, Ho CTK, et al. Do flares of systemic lupus erythematosus decline after menopause? Scand J Rheumatol 1999;28:360-5.
46. Bruce IN, Laskin CA. Sex hormones in systemic lupus erythematosus: a controversy for modern times. J Rheumatol 1997;24:1461-3.
47. Petri M. Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy. Lupus 2001;10:222-6.
48. Julkunen HA. Oral contraceptives in systemic lupus erythematosus: side effects and influence on the activity of SLE. Scand J Rheumatol 1991;20:427-33.
49. Jungers P, Dougados M, Pelissier C, et al. Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum 1982;25:618-23.
50. Ho CTK, Mok CC, Lau CS, et al. Late onset systemic lupus erythematosus in southern Chinese. Ann Rheum Dis 1998;57:437-40.
51. Rood MJ, Van Der Velde EA, Ten Cate R, et al. Female sex hormones at the onset of systemic lupus erythematosus affect survival. Br J Rheumatol 1998;37:1008-10.
52. Berczi I. The immunology of prolactin. Semin Reprod Endocrinol 1992;10:196-219.
53. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation 1997;4:171-80.
54. Cross RJ, Campbell JL, Roszman TL. Potentiation of antibody responsiveness after the transplantation of a syngeneic pituitary gland. Neuroimmunology 1989;25:29-35.
55. Walker SE, Allen SH, McMurray RW. Prolactin and autoimmune disease. Trends Endocrinol Metab 1993;4:147-51.
56. Peeva E, Grimaldi C, Spatz L, et al. Bromocriptine restores tolerance in estrogen-treated mice. J Clin Invest 2000;106:1373-9.
57. Lavalle C, Loyo E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 1987;14:268-72.
58. Jara LJ, Gomez-Sanchez C, Silveira LH, et al. Hyperprolactinemia in systemic lupus erythematosus: association with disease activity. Am J Med Sci 1992;303:222-6.
59. Buskila D, Lorber M, Neumann L, et al. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol 1996;23:629-32.
60. Miranda JM, Prieto RE, Paniagua R, et al. Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis. Lupus 1998;7:387-91.
61. Pacilio M, Migliaresi S, Meli R, et al. Elevated bioactive prolactin levels in systemic lupus erythematosus - association with disease activity. J Rheumatol 2001;28:2216-21.
62. Mok CC, Lau CS, Tam SC. Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients. Br J Rheumatol 1997;36:986-9.
63. Mok CC, Lau CS, Lee KW, et al. Hyperprolatinemia in males with systemic lupus erythematosus. J Rheumatol 1998;25:2357-63.
64. Ostendorf B, Fischer R, Santen R, et al. Hyperprolactinemia in systemic lupus erythematosus? Scand J Rheumatol 1996;25:97-102.
65. McMurray RW, Weidensaul D, Allen SH, et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol 1995;22:2084-91.
66. Walker SE, Reddy GH, Miller D, et al. Treatment of active systemic lupus erythematosus with the prolactin lowering drug, bromocriptine: comparison with hydroxychloroquine in a randomized, blinded one-year study. Arthritis Rheum 1999;42:S282 [abstract 1267].
67. Grasso G, Massai L, De Leo V, et al. The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro. Life Sci 1998;62:2005-14.
68. Jacobson JD, Nisula BC, Steinberg AD. Modulation of the expression of murine lupus by gonadotropin-releasing hormone analogs. Endocrinology 1994;134:2516-23.
69. Jacobson JD, Ansari MA, Kinealy M, et al. Gender-specific exacerbation of murine lupus by gonadotropin-releasing hormone: potential role of G alpha(q/11). Endocrinology 1999;140:3429-37.
70. Sternberg EM, Hill JM, Chrousos GP, et al. Inflammatory mediator-induced hypothalamic-pituitary-adrenal axis activation is defective in streptococcal cell wall arthritis-susceptible Lewis rats. Proc Natl Acad Sci U S A 1989;86:2374-8.
71. Lechner O, Dietrich H, Oliveira dos Santos A, et al. Altered circadian rhythms of the stress hormone and melatonin response in lupus-prone MRL/MP-fas(lpr) mice. J Autoimmun 2000;14:325-33.
72. Shanks N, Moore PM, Perks P, et al. Alterations in hypothalamic-pituitary-adrenal function correlated with the onset of murine SLE in MRL +/+ and lpr/lpr mice. Brain Behav Immun 1999;13:348-60.
73. Gutierrez MA, Garcia ME, Rodriguez JA, et al. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus 1998;7:404-8.
74. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
75. Vlahakos D, Foster MH, Ucci AA, et al. Murine monoclonal anti-DNA antibodies penetrate cells, bind to nuclei, and induce glomerular proliferation and proteinuria in vivo. J Am Soc Nephrol 1992;2:1345-54.
76. Ehrenstein MR, Katz DR, Griffiths MH, et al. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int 1995;48:705-11.
77. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68.
78. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;24;345:1595-9.
79. Foster MH, Cizman B, Madaio MP. Nephritogenic autoantibodies in systemic lupus erythematosus: immunochemical properties, mechanisms of immune deposition, and genetic origins. Lab Invest 1993;69:494-507.
80. van Bruggen MC, Kramers C, Walgreen B, et al. Nucleosomes and histones are present in glomerular deposits in human lupus nephritis. Nephrol Dial Transplant 1997;12:57-66.
81. James JA, Gross T, Scofield RH, et al. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 1995;181:453-61.
82. Klinman DM, Shirai A, Ishigatsubo Y, et al. Quantitation of IgM- and IgG-secreting B cells in the peripheral blood of patients with systemic lupus erythematosus. Arthritis Rheum 1991;34:1404-10.
83. Liossis SN, Kovacs B, Dennis G, et al. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest 1996;98:2549-57.
84. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991;147:117-23.
85. Monneaux F, Muller S. Epitope spreading in systemic lupus erythematosus: identification of triggering peptide sequences. Arthritis Rheum 2002;46:1430-8.
86. Bakke AC, Kirkland PA, Kitridou RC, et al. T lymphocyte subsets in systemic lupus erythematosus. Correlations with corticosteroid therapy and disease activity. Arthritis Rheum 1983;26:745-50.
87. Linker-Israeli M, Quismorio FP Jr, Horwitz DA. CD8+ lymphocytes from patients with systemic lupus erythematosus sustain, rather than suppress, spontaneous polyclonal IgG production and synergize with CD4+ cells to support autoantibody synthesis. Arthritis Rheum 1990;33:1216-25.
88. Portales-Perez D, Gonzalez-Amaro R, Abud-Mendoza C, et al. Abnormalities in CD69 expression, cytosolic pH and Ca2+ during activation of lymphocytes from patients with systemic lupus erythematosus. Lupus 1997;6:48-56.
89. Fernandez-Gutierrez B, de Miguel S, Morado C, et al. Defective early T and T-dependent B cell activation in systemic lupus erythematosus. Lupus 1998;7:314-22.
90. Horwitz DA, Garrett MA. Lymphocyte reactivity to mitogens in subjects with systemic lupus erythematosus, rheumatoid arthritis and scleroderma. Clin Exp Immunol 1977;27:92-9.
91. Alcocer-Varela J, Alarcon-Segovia D. Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 1982;69:1388-92.
92. Warrington RJ. Interleukin-2 abnormalities in systemic lupus erythematosus and rheumatoid arthritis. A role for overproduction of interleukin-2 in human autoimmunity? J Rheumatol 1988;15:616-20.
93. Linker-Israeli M, Bakke AC, Kitridou RC, et al. Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE). J Immunol 1983;130:2651-5.
94. Garcia-Cozar FJ, Molina IJ, Cuadrado MJ, et al. Defective B7 expression on antigen-presenting cells underlying T cell activation abnormalities in systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 1996;104:72-9.
95. Lauwerys BR, Houssiau FA. Cytokines: clues to the pathogenesis of SLE. Lupus 1998;7:211-13.
96. Horwitz DA, Wang H, Gray JD. Cytokine gene profile in circulating blood mononuclear cells from patients with systemic lupus erythematosus: increased interleukin-2 but not interleukin-4 mRNA. Lupus 1994;3:423-8.
97. Murakawa Y, Sakane T. Deficient phytohemagglutinin-induced interleukin-2 activity in patients with inactive systemic lupus erythematosus is correctable by the addition of phorbol myristate acetate. Arthritis Rheum 1988;31:826-33.
98. Llorente L, Richaud-Patin Y, Wijdenes J, et al. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur Cytokine Netw 1993;4:421-7.
99. Llorente L, Richaud-Patin Y, Fior R, et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus. A potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994;37:1647-55.
100. Csiszar A, Nagy G, Gergely P, et al. Increased interferon-gamma (IFN-gamma), IL-10 and decreased IL-4 mRNA expression in peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 2000;122:464-70.
101. Houssiau FA, Lefebvre C, Vanden Berghe M, et al. Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 1995;4:393-5.
102. Park YB, Lee SK, Kim DS, et al. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8.
103. Grondal G, Gunnarsson I, Ronnelid J, et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:565-70.
104. Hagiwara E, Gourley MF, Lee S, et al. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10 : interferon-gamma-secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-85.
105. Lauwerys BR, Garot N, Renauld JC, et al. Interleukin-10 blockade corrects impaired in vitro cellular immune responses of systemic lupus erythematosus patients. Arthritis Rheum 2000;43:1976-81.
106. Tyrrell-Price J, Lydyard PM, Isenberg DA. The effect of interleukin-10 and of interleukin-12 on the in vitro production of anti-double-stranded DNA antibodies from patients with systemic lupus erythematosus. Clin Exp Immunol 2001;124:118-25.
107. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84:4008-27.
108. Horwitz DA, Gray JD, Behrendsen SC, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998;41:838-44.
109. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998;10:140-7.
110. Liu TF, Jones BM. Impairment of IL-12 production in SLE is due to defective monocytes, not B cells. Immunol Lett 1997;56:314.
111. Houssiau FA, Mascart-Lemone F, Stevens M, et al. IL-12 inhibits in vitro immunoglobulin production by human lupus peripheral blood mononuclear cells (PBMC). Clin Exp Immunol 1997;108:375-80.
112. Mir A, Porteu F, Levy M, et al. C3b receptor (CR1) on phagocytic cells from SLE patients: analysis of the defect and familial study. Clin Exp Immunol 1988;73:461-6.
113. Kiss E, Csipo I, Cohen JH, et al. CR1 density polymorphism and expression on erythrocytes of patients with systemic lupus erythematosus. Autoimmunity 1996;25:53-8.
114. Dijstelbloem HM, Bijl M, Fijnheer R, et al. Fcgamma receptor polymorphisms in systemic lupus erythematosus: association with disease and in vivo clearance of immune complexes. Arthritis Rheum 2000;43:2793-800.
115. Zuniga R, Ng S, Peterson MG, et al. Low-binding alleles of Fcgamma receptor types IIA and IIIA are inherited independently and are associated with systemic lupus erythematosus in Hispanic patients. Arthritis Rheum 2001;44:361-7.
116. Herrmann M, Voll RE, Zoller OM, et al. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
117. Mohan C, Adams S, Stanik V, et al. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J Exp Med 1993;177:1367-81.
118. Filaci G, Bacilieri S, Fravega M, et al. Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol 2001;166:6452-7.
119. Sherer Y, Shoenfeld Y. Idiotypic network dysregulation: a common etiopathogenesis of diverse autoimmune diseases. Appl Biochem Biotechnol 2000;83:155-62.
120. Suzuki N, Ichino M, Mihara S, et al. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:344-53.
121. Theofilopoulos AN, Dixon FJ. Etiopathogenesis of murine SLE. Immunol Rev 1981;55:179-216.
122. Takahashi T, Tanaka M, Brannan CI, et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-76
123. McNally J, Yoo DH, Drappa J, et al. Fas ligand expression and function in systemic lupus erythematosus. J Immunol 1997;159:4628-36.
124. Wu J, Wilson J, He J, et al. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 1996;98:1107-13.
125. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol 1994;152:3685-92.
126. Courtney PA, Crockard AD, Williamson K, et al. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999;8:508-13.
127. Shoshan Y, Shapira I, Toubi E, et al. Accelerated Fas-mediated apoptosis of monocytes and maturing macrophages from patients with systemic lupus erythematosus: relevance to in vitro impairment of interaction with iC3b-opsonized apoptotic cells. J Immunol 2001;167:5963-69.
128. Baumann I, Kolowos W, Voll RE, et al. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002;46:191-201.
129. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998;199:265-85.
130. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997;158:4525-8.
131. Botto M, Dell'Agnola C, Bygrave AE, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998;19:56-9.
132. Haseley LA, Wisnieski JJ, Denburg MR, et al. Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fc gamma RIIA alleles. Kidney Int 1997;52:1375-80.
133. Salmon M, Gordon C. The role of apoptosis in systemic lupus erythematosus. Rheumatology (Oxford) 1999;38:1177-83.
134. Adams LE, Mongey AB. Role of genetic factors in drug-related autoimmunity. Lupus 1994;3:443-7.
135. Reidenberg MM, Drayer DE, Lorenzo B, et al. Acetylation phenotypes and environmental chemical exposure of people with idiopathic systemic lupus erythematosus. Arthritis Rheum 1993;36:971-3.
136. Freni-Titulaer LW, Kelley DB, Grow AG, et al. Connective tissue disease in southeastern Georgia: a case-control study of etiologic factors. Am J Epidemiol 1989;130:404-9.
137. Petri M, Allbritton J. Hair product use in systemic lupus erythematosus. A case-control study. Arthritis Rheum 1992;35:625-9.
138. Sanchez-Guerrero J, Karlson EW, Colditz GA, et al. Hair dye use and the risk of developing systemic lupus erythematosus. Arthritis Rheum 1996;39:657-62.
139. Cooper GS, Dooley MA, Treadwell EL, et al. Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus. J Rheumatol 2001;28:2653-6.
140. Furukawa F, Kashihara-Sawami M, Lyons MB, et al. Binding of antibodies to the extractable nuclear antigens SS-A/Ro and SS-B/La is induced on the surface of human keratinocytes by ultraviolet light (UVL): implications for the pathogenesis of photosensitive cutaneous lupus. J Invest Dermatol 1990;94:77-85.
141. Casciola-Rosen L, Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997;6:175-80.
142. Casciola-Rosen L, Andrade F, Ulanet D, et al. Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity. J Exp Med 1999;190:815-26.
143. Prete PE. The mechanism of action of L-canavonine in inducing autoimmune phenomena. Arthritis Rheum 1985;28:1198-200.
144. Herrmann M, Hagenhofer M, Kalden JR. Retroviruses and systemic lupus erythematosus. Immunol Rev 1996;152:145-56.
145. Ahmed SA, Hissong BD, Verthelyi D, et al. Gender and risk of autoimmune diseases: possible role of estrogenic compounds. Environ Health Perspect 1999;107(suppl 5):681-6.
146. Marselos M, Tomatis L. Diethylstilboestrol. II: Pharmacology, toxicology and carcinogenicity in experimental animals. Eur J Cancer 1993;29A:149-55.
147. Noller KL, Blair PB, O'Brien PC, et al. Increased occurrence of autoimmune disease among women exposed in utero to diethylstilbestrol. Fertil Steril 1988;49:1080-2.